Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Infectious disease

Methylation makes a difference

Many antigens are heavily glycosylated; however, the peptides that are presented by classical MHC class I and class II molecules are not usually post-translationally modified. Now, a study published in Nature Medicine shows that methylation of the Mycobacterium tuberculosis antigen heparin-binding haemagglutinin (HBHA) is crucial for the induction of protective T-cell immunity to this pathogen.

HBHA is a cell-surface protein antigen, and the native protein (nHBHA) is post-translationally modified by methylation of lysine-rich repeats in the carboxy-terminal domain; however, recombinant HBHA (rHBHA) produced by Escherichia coli is not methylated. Because T cells that are isolated from healthy humans infected with M. tuberculosis produce large amounts of interferon-γ (IFN-γ) in response to HBHA, whereas T cells from patients with active tuberculosis do not, Temmerman et al. investigated the role of HBHA methylation in the immune response to M. tuberculosis.

Peripheral-blood mononuclear cells (PBMCs) from healthy individuals infected with M. tuberculosis secreted greater levels of IFN-γ in response to nHBHA than in response to rHBHA, and the proportion of individuals with nHBHA-responsive PBMCs was much greater for the healthy infected individuals than for patients with tuberculosis. The importance of methylation was confirmed by the observation that IFN-γ production was enhanced when rHBHA was methylated in vitro and by the finding that splenocytes from mice infected with Mycobacterium bovis bacillus Calmette-Guérin (BCG) produced considerably more IFN-γ in response to nHBHA than in response to rHBHA.

Importantly, the response induced by nHBHA and rHBHA, despite differing in magnitude, was mediated by both MHC-class-II-restricted CD4+ T cells and classical MHC-class-I-restricted CD8+ T cells. Further analysis using a panel of sequential, overlapping peptides that spanned the HBHA sequence provided some evidence to support the hypothesis that the methylated portion of HBHA forms part of the T-cell epitopes.

IFN-γ is crucial for defence against mycobacterial infection, so the protective potential of nHBHA was assessed. In two mouse models of disease, animals immunized with nHBHA and adjuvant and then challenged with a virulent strain of M. tuberculosis were protected from disease to the same extent as animals vaccinated with BCG, whereas mice immunized with rHBHA were not protected. The distinct abilities of nHBHA and rHBHA to induce protection correlated with splenocytes from nHBHA-immunized mice producing considerably more IFN-γ in response to bone-marrow-derived macrophages pulsed with M. tuberculosis and more-efficiently lysing BCG-loaded macrophages.

This report indicates that HBHA methylation modifies the cellular immune response that it elicits. Because HBHA methylation is essential for the induction of a protective immune response against M. tuberculosis that is comparable with the response generated by vaccination with BCG, the authors suggest that this antigen could be used to generate new vaccines against tuberculosis.

ORIGINAL RESEARCH PAPER

  1. 1

    Temmerman, S. et al. Methylation-dependent T cell immunity to Mycobacterium tuberculosis heparin-binding hemagglutinin. Nature Med. 8 August 2004 (doi:10/1038/nm1090).

Download references

Authors

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Honey, K. Methylation makes a difference. Nat Rev Immunol 4, 658 (2004). https://doi.org/10.1038/nri1444

Download citation

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing